5:24 PM
Jan 08, 2013
 |  BC Extra  |  Top Story

Bind, Amgen in Accurin deal

Bind Biosciences Inc. (Cambridge, Mass.) and Amgen Inc. (NASDAQ:AMGN) partnered to develop and commercialize an Accurin therapeutic for solid tumor indications to be selected by Amgen. Accurins are selective and programmable nanoparticle-encapsulated therapeutics that are designed to...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >